Please login to the form below

Not currently logged in

Biosimilar Lantus leads CHMP opinions

Boehringer and Lilly’s insulin one of six new medicines recommended for EU approval

Six new medicines have received backing for use in the EU by the advisory body to the European Medicines Agency (EMA).

Leading the pack is Abasria, a biosimilar version of Sanofi's huge-selling insulin glargine Lantus, which is recommended to treat people with both type 1 and type 2 diabetes who are unable to control blood sugar levels.

Abasria was developed by Boehringer Ingelheim and Lilly and is the first biosimilar insulin to be recommended by the Committee for Medicinal Products for Human Use (CHMP).

The decision opens the door for Lilly and Boehringer to offer a direct challenge to Sanofi once Lantus' patent expires in the next couple of years. Once launched it could make a serious dent in Lantus revenues, which peaked at more than $7bn last year, making it the seventh highest grossing drug in the world.

Sanofi is not lying still though and has a new version of Lantus in the works, called Toujeo, which has a reduced risk of hypoglycaemia. Speaking to PMLiVE at this month's American Diabetes Association meeting, Sanofi's Pierre Chancel confirmed the company plans to push for doctors to switch from Lantus to Toujeo.

Recommendations in hepatitis C and HIV

Other significant recommendations by the CHMP included Bristol-Myers Squibb's (BMS) Daklinza (daclatasvir), which was backed for use as a treatment for chronic hepatitis C.

It is one of several new oral therapies that are transforming the still problematic hepatitis C market. Gilead Sciences' Sovaldi (sofosbuvir) is emerging as the leader in the field, although there is further competition from Janssen and Merck & Co.

ViiV Healthcare, a joint venture between GlaxoSmithKline, Pfizer and Shionogi, also scored a recommendation in infectious diseases.

Triumeq – a combination of already-approved treatments Tivicay (dolutegravir) and Kivexa (abacavir/lamivudine) – was recommended to treat HIV infection in adults and adolescents aged 12 years and older. It gives patients a more convenient single-tablet option.

Elsewhere, the CHMP also backed a combination of Clopidogrel and acetylsalicylic acid to be marketed by Teva for the prevention of atherothrombotic event.

In addition GE Healthcare received a positive opinion for Vizamyl (flutemetamol) as a diagnostic for Alzheimer's disease. Vizamyl is a biomarker that can detect amyloid-beta neuritic plaques, where are formations in the brain associated with Alzheimer's.

The final new medicine recommended for use in the EU is Velphoro (sucroferric oxyhydroxide), to be marketed by Vifor Fresenius Medical Care Renal Pharma. The drug is recommended to control levels of serum phosphorus levels in adult patients with chronic kidney disease on haemodialysis or peritoneal dialysis.

Article by
Thomas Meek

30th June 2014

From: Sales, Regulatory



COVID-19 Updates and Daily News

Featured jobs


Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...